Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
162 hedge funds and large institutions have $877M invested in Achillion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 9 closing their positions.
196% more call options, than puts
Call options by funds: $13M | Put options by funds: $4.38M
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
30% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 44
10% more funds holding
Funds holding: 147 → 162 (+15)
3% more capital invested
Capital invested by funds: $853M → $877M (+$24.3M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.71% less ownership
Funds ownership: 79.99% → 79.27% (-0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$12.9M |
| 2 |
O
OrbiMed
New York
|
+$12.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$7.9M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
+$7.88M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$7.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.4M |
| 2 |
Millennium Management
New York
|
-$26.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.9M |
| 5 |
JP Morgan Chase
New York
|
-$5.14M |
ACHN Hedge Fund Activity: Q3 2016 in Review
162 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2016, worth a combined $877M — up 2.9% from $853M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ACHN positions and 9 closed out — a net gain of 16 holders — while 57 added to existing stakes and 44 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $12.9M. The largest seller was Fidelity Investments, cutting an estimated $37.4M.
- 162 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2016, up from 147 in Q2 2016.
- Funds reported $877M of Achillion Pharmaceuticals stock for Q3 2016, up 2.9% quarter-over-quarter.
- 25 funds opened new Achillion Pharmaceuticals positions in Q3 2016 and 9 closed out, a net change of +16 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2016 was Goldman Sachs, an estimated $12.9M added.
- The largest Achillion Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $37.4M sold.
Based on aggregated 13F filings for Q3 2016.